Clinical Trials Browser

Completed × Has results × pazopanib × Clear all

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT00720941 2025-03-30

COMPARZ

Phase 3 Completed

1,110 enrolled 27 charts

Carcinoma, Renal Cell

NCT01147822 2025-03-28

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 2 Completed

367 enrolled 14 charts

Carcinoma, Renal Cell

NCT01767636 2025-03-03

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

38 enrolled 12 charts

Oncocytoma, renal, Carcinoma, Renal Cell

NCT02049905 2024-06-13

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Phase 3 Completed

433 enrolled 10 charts

Neoplasm Metastasis, Sarcoma

NCT00827372 2023-10-16

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Phase 2 Completed

10 enrolled 10 charts

Lymphedema

NCT03200717 2023-08-21

IO-PAZ

Phase 2 Completed

62 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01330966 2023-03-10

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Phase 2 Completed

47 enrolled 10 charts

Chondrosarcoma

NCT01462630 2022-08-19

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase 2 Completed

29 enrolled 10 charts

Hemangiosarcoma, Sarcoma

NCT01468922 2022-07-01

Pazopanib and ARQ 197 for Advanced Solid Tumors

Phase 1 Completed

32 enrolled 21 charts

Neoplasms, Sarcoma

NCT01498458 2022-06-10

PazoX

Phase 1 Completed

9 enrolled 15 charts

Breast Neoplasms

NCT01157091 2022-06-08

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Phase 2 Completed

28 enrolled 10 charts

Carcinoma, Renal Cell

NCT01664182 2022-06-07

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Phase 2 Completed

41 enrolled 13 charts

Carcinoma, Renal Cell

NCT02357810 2022-06-07

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Phase 2 Completed

178 enrolled 16 charts

Liposarcoma, Sarcoma, Osteosarcoma

NCT01472081 2021-12-02

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Phase 1 Completed

194 enrolled 18 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT01532687 2021-09-27

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Phase 2 Completed

54 enrolled 12 charts

Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

69 enrolled 15 charts

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT01465659 2021-08-05

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Phase 1/2 Completed

29 enrolled 16 charts

Carcinoma, Islet Cell

NCT01610206 2021-02-25

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Phase 2 Completed

148 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT00866697 2021-02-16

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Completed

940 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01235962 2020-11-23

PROTECT

Phase 3 Completed

1,538 enrolled 27 charts

Carcinoma, Renal Cell, Neoplasms

NCT01956669 2020-08-12

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

Phase 2 Completed

57 enrolled 22 charts

Sarcoma

NCT02300545 2020-08-05

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Phase 2 Completed

56 enrolled 11 charts

Sarcoma

NCT01466972 2020-07-08

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Phase 2 Completed

30 enrolled 11 charts

Breast Neoplasms, Neoplasms

NCT01975519 2020-05-20

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Phase 1/2 Completed

111 enrolled 15 charts

Hemangiosarcoma, Sarcoma

NCT02979899 2020-05-12

TAPPAS

Phase 3 Completed

128 enrolled 13 charts

Hemangiosarcoma

NCT01446809 2020-04-13

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Phase NA Completed

23 enrolled 16 charts

Sarcoma

NCT01593748 2020-04-06

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Phase 2 Completed

90 enrolled 12 charts

Sarcoma

NCT00454363 2020-04-03

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Phase 2 Completed

52 enrolled 11 charts

Glucagonoma, Insulinoma, Somatostatinoma, Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia Type 1

NCT00625846 2020-02-26

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Phase 2 Completed

152 enrolled 16 charts

EndocrineHead & Neck

Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT01184326 2019-10-02

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Phase 1 Completed

23 enrolled 16 charts

Kidney Neoplasms

NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase 2 Completed

22 enrolled 8 charts

GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT01107665 2019-08-07

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

Phase 2 Completed

60 enrolled 16 charts

Melanoma

NCT02729194 2019-06-10

Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma

Phase EARLY_PHASE1 Completed

16 enrolled 17 charts

Carcinoma, Renal Cell

NCT01280201 2019-05-29

Pazopanib as Single Agent in Advanced NETs

Phase 2 Completed

44 enrolled 17 charts

Neuroendocrine Tumors

NCT01253369 2019-04-23

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Completed

33 enrolled 8 charts

Lung Neoplasms, Small Cell Lung Carcinoma

NCT01832259 2018-12-12

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

Phase 2 Completed

30 enrolled 10 charts

Adenocarcinoma of the Prostate

NCT00861913 2018-10-16

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Phase 2 Completed

13 enrolled 8 charts

Melanoma

NCT00281632 2018-09-17

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Phase 2 Completed

35 enrolled 24 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01158521 2018-09-12

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Phase 2 Completed

25 enrolled 8 charts

Carcinoma, Renal Cell

NCT00509587 2018-08-08

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2 Completed

21 enrolled 10 charts

Breast Neoplasms

NCT01361113 2018-04-25

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Phase 2 Completed

21 enrolled 10 charts

Carcinoma, Renal Cell

NCT01108055 2017-06-09

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Phase 2 Completed

43 enrolled 16 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01064310 2017-04-17

PISCES

Phase 3 Completed

169 enrolled 16 charts

Carcinoma, Renal Cell, Neoplasms, Patient Preference

NCT00800345 2017-03-28

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

Phase 1 Completed

33 enrolled 7 charts

Gynecologic Tumors

NCT00459381 2017-03-15

Pazopanib in Treating Patients With Recurrent Glioblastoma

Phase 2 Completed

35 enrolled 12 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01262820 2017-03-07

LCCC0921

Phase 2 Completed

15 enrolled 10 charts

Lung Neoplasms

NCT01506596 2017-02-15

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Phase 2 Completed

42 enrolled 9 charts

Liposarcoma

NCT00347919 2016-02-25

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Phase 2 Completed

189 enrolled 15 charts

Breast Neoplasms, Neoplasm Metastasis